Advertisement

European Journal of Clinical Pharmacology

, Volume 21, Issue 4, pp 315–323 | Cite as

Pharmacokinetics of bendroflumethiazide alone and in combination with propranolol and hydralazine

  • M. Schäfer-Korting
  • E. Mutschler
Originals

Summary

Bendroflumethiazide (Bft) was administered to 6 healthy subjects at 3 different dose levels (2.5, 5 and 10 mg) in a cross-over design, either as capsules (2.5 mg) or as tablets (5 mg). Its pharmacokinetics were evaluated then and following administration of a fixed combination of Bft with propranolol and hydralazine to a further 7 volunteers. Plasma and urinary concentrations of Bft were determined by a new fluorimetric — thin-layer chromotography procedure. Peak plasma levels occurred after 2–3 h and averaged 15, 27 and 45 µg/l in the three dose groups. Areas under the plasma concentration — time curves (AUC0→12), which were 75, 147 and 250 µg l−1 h respectively, and cumulative urinary recovery (20%) were independent of the dose administered and the type of formulation. Thus Bft kinetics proved to be linear within the dose range evaluated. The plasma clearance was calculated to be 505 ml/min, renal clearance 108 ml/min and nonrenal clearance 396 ml/min. Bioavailability of Bft was not altered following administration of the fixed combination. The amount of propranolol found in the circulation did not change, whereas that of hydralazine (determined as apparent hydralazine) increased by 59% when the fixed combination was administered.

Key words

bendroflumethiazide propranolol hydralazine pharmacokinetics thin-layer chromatography fluorimetry fixed combination product 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Beermann B, Groschinsky-Grind M, Lindström B, Wikland B (1978) Pharmacokinetics of bendroflumethiazide in hypertensive patients. Eur J Clin Pharmacol 13: 119–124Google Scholar
  2. 2.
    Dollery CT (1977) Pharmacological basis for combination therapy of hypertension. Ann Rev Pharmacol Toxicol 17: 311–323Google Scholar
  3. 3.
    Baber NS, Dawes PM (1979) β-Adrenoceptor blocking drugs and diuretics in hypertension. Br J Clin Pharmacol 7: 404–405Google Scholar
  4. 4.
    Solomon LR, Dawes PM (1980) Treatment of essential hypertension with a combination of propranolol and bendrofluazide. J Intern Med Res 8: 34–37Google Scholar
  5. 5.
    Dawson A, Johnson BF, Smith IK, Munro-Faure AD (1979) A comparison of the effects of labetalol, bendrofluazide and their combination in hypertension. Br J Clin Pharmacol 8: 149–154Google Scholar
  6. 6.
    Brettell HR, Smith JG, Aikawa JK (1964) S35-labelled bendroflumethiazide in human beings. Arch Intern Med 113: 373–377Google Scholar
  7. 7.
    Beermann B, Groschinsky-Grind M, Lindström B (1976) A glc assay for bendroflumethiazide. Preliminary data about its plasma levels in man. Eur J Clin Pharmacol 10: 293–295Google Scholar
  8. 8.
    Beermann B, Groschinsky-Grind M, Lindström B (1977) Pharmacokinetics of bendroflumethiazide. Clin Pharmacol Ther 22: 385–388Google Scholar
  9. 9.
    Beermann B, Groschinsky-Grind M, Lindström B (1978) Effect of food on the bioavailability of bendroflumethiazide. Acta Med Scand 204: 291–293Google Scholar
  10. 10.
    Schäfer M, Geißler HE, Mutschler E (1977) Fluorimetrische Bestimmung von Propranolol und seines Metaboliten N-Desisopropylpropranolol in Plasma und Urin durch direkte Auswertung von Dünnschichtchromatogrammen. J Chromatogr Biomed Appl 143: 607–613Google Scholar
  11. 11.
    Jack DB, Brechbühler S, Degen PH, Zbinden P, Riess W (1975) The determination of hydralazine in plasma by gas-liquid chromatography. J Chromatogr 115: 87–92Google Scholar
  12. 12.
    Zak SB, Lukas G, Gilleran TG (1977) Plasma levels of real and “apparent” hydralazine in man and rat. Drug Metab Dispos 5: 116–121Google Scholar
  13. 13.
    Wagner JG (1975) Fundamentals of clinical pharmacokinetics. Drug Intelligence Publications, Hamilton, Illinois, pp 177–181Google Scholar
  14. 14.
    Ronfeld AR, Benet LZ (1977) Interpretation of plasma concentration-time curves after oral dosing. J Pharm Sci 66: 178–180Google Scholar
  15. 15.
    Walle T, Conradi EC, Walle K, Fagan TC, Gaffney TE (1978) The predictable relationship between plasma levels and dose during chronic propranolol therapy. Clin Pharmacol Ther 24: 668–677Google Scholar
  16. 16.
    Talseth T (1976) Studies on hydralazine. III. Bioavailability of hydralazine in man. Eur J Clin Pharmacol 10: 395–401Google Scholar
  17. 17.
    McLean AJ, Skews H, Bobik A, Dudley FJ (1980) Interaction between oral propranolol and hydralazine. Clin Pharmacol Ther 27: 726–732Google Scholar
  18. 18.
    Melander A, Danielson K, Schersten B, Wåhlin E (1977) Enhancement of the bioavailability of propranolol and metoprolol by food. Clin Pharmacol Ther 22: 108–112Google Scholar
  19. 19.
    Goodman LS, Gilman A (1980) The pharmacological basis of therapeutics 6th ed. Macmillan, New YorkGoogle Scholar
  20. 20.
    Lutterodt A, Nattel S, McLeod J (1980) Duration of antihypertensive effect of a single daily dose of hydrochlorothiazide. Clin Pharmacol Ther 27: 324–327Google Scholar
  21. 21.
    Serlin MJ, Orme MLE, Baber NS, Sibeon RG, Laws E, Breckenridge A (1980) Propranolol in the control of blood pressure: A dose-response study. Clin Pharmacol Ther 27: 586–592Google Scholar

Copyright information

© Springer-Verlag 1982

Authors and Affiliations

  • M. Schäfer-Korting
    • 1
  • E. Mutschler
    • 1
  1. 1.Pharmakologisches Institut für Naturwissenschaftler der Johann Wolfgang Goethe-UniversitätFrankfurt/MainGermany

Personalised recommendations